Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25651325 | 0.86 | TACR1 (0.40) | TACR1MEN1KMT2A | |
| SCHEMBL25651297 | 0.78 | HSP90AA1 (0.31) | MEN1ALDH1A1LMNACYP1A2CYP3A4 | |
| SCHEMBL25613551 | 0.78 | ITGB2 (0.37) | TACR1MEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL25645172 | 0.73 | HTR2C (0.30) | — | |
| SCHEMBL25628893 | 0.72 | PKM (0.38) | MEN1LMNAKMT2A | |
| SCHEMBL25651296 | 0.71 | SLC6A2 (0.32) | — | |
| SCHEMBL24005504 | 0.70 | P2RX7 (0.41) | TACR1MEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL25628689 | 0.70 | ITGB2 (0.36) | MEN1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL25478787 | 0.69 | KMT2A (0.38) | TACR1MEN1ALDH1A1LMNACYP1A2 | |
| SCHEMBL25613548 | 0.69 | BLM (0.39) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | TACR1 4609/4885MEN1 4012/4885ALDH1A1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.